FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149771890> ?p ?o ?g. }

• W2149771890 endingPage "2247" @default.
• W2149771890 startingPage "2242" @default.
• W2149771890 abstract "Background. Cardiotoxicity related to the widely used cytotoxic compound 5-fluorouracil (5-FU) is rare compared with the frequency observed with the use of anthracyclines. More effective protocols incorporating active biomodulatory compounds like folinic acid (FA) or combination chemotherapy change type and severity of toxicity as well. The objective of the current study was to assess cardiotoxicity of the combination 5-FU and folinic acid. Methods. The authors' multicenter experience with 390 patients treated for advanced gastrointestinal cancer with intermediate-dose folinic acid and 5-FU was reviewed. Results. The overall risk of cardiotoxicity was 3%, which is not significantly higher than that reported with 5-FU alone. Eight of 53 patients with a history of cardiac disease reported cardiac symptoms (15.1%), compared with 5 of 337 patients (1.5%) with a no history of cardiac disease. Median time to symptoms was 3 days (range, 2–6). Nine patients had symptoms resembling myocardial ischemia, one patient died due to assumed myocardial infarction related closely to fluorouracil treatment, four patients had supraventricular arrhythmia, and one patient had congestive heart failure. A history of cardiac disease was the only risk factor associated with cardiotoxicity. Relapses were frequent on reinstitution of therapy despite cardiac symptoms in the preceding cycle. Therapeutically or prophylactically administered nitrates had no significant effect. Conclusion. Physicians should be aware of the cardiotoxic properties of active fluorouracil treatment. The combination of 5-FU and leucovorin does not differ from single-agent therapy in frequency or type of cardiotoxicity. Close monitoring of patients is mandatory, especially for those patients at high risk for cardiac side effects. Treatment should be discontinued if coronary symptoms develop, because neither effective treatment nor prophylaxis exists for such symptoms." @default.
• W2149771890 created "2016-06-24" @default.
• W2149771890 creator A5014640874 @default.
• W2149771890 creator A5018711955 @default.
• W2149771890 creator A5033935778 @default.
• W2149771890 creator A5033999259 @default.
• W2149771890 creator A5036532882 @default.
• W2149771890 creator A5041469238 @default.
• W2149771890 creator A5043893807 @default.
• W2149771890 creator A5046222147 @default.
• W2149771890 creator A5050929435 @default.
• W2149771890 creator A5065548109 @default.
• W2149771890 creator A5074542184 @default.
• W2149771890 creator A5078383767 @default.
• W2149771890 creator A5080736266 @default.
• W2149771890 date "1993-10-01" @default.
• W2149771890 modified "2023-10-02" @default.
• W2149771890 title "Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer" @default.
• W2149771890 cites W100634000 @default.
• W2149771890 cites W1844072307 @default.
• W2149771890 cites W1883602322 @default.
• W2149771890 cites W1980253503 @default.
• W2149771890 cites W2003865898 @default.
• W2149771890 cites W2013349394 @default.
• W2149771890 cites W2037990754 @default.
• W2149771890 cites W2049266649 @default.
• W2149771890 cites W2062636381 @default.
• W2149771890 cites W2079709100 @default.
• W2149771890 cites W2081500693 @default.
• W2149771890 cites W2083138221 @default.
• W2149771890 cites W2107147293 @default.
• W2149771890 cites W2155123572 @default.
• W2149771890 cites W2284629536 @default.
• W2149771890 cites W97206418 @default.
• W2149771890 cites W2094627445 @default.
• W2149771890 doi "https://doi.org/10.1002/1097-0142(19931001)72:7<2242::aid-cncr2820720730>3.0.co;2-e" @default.
• W2149771890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8374883" @default.
• W2149771890 hasPublicationYear "1993" @default.
• W2149771890 type Work @default.
• W2149771890 sameAs 2149771890 @default.
• W2149771890 citedByCount "94" @default.
• W2149771890 countsByYear W21497718902012 @default.
• W2149771890 countsByYear W21497718902013 @default.
• W2149771890 countsByYear W21497718902014 @default.
• W2149771890 countsByYear W21497718902015 @default.
• W2149771890 countsByYear W21497718902016 @default.
• W2149771890 countsByYear W21497718902017 @default.
• W2149771890 countsByYear W21497718902018 @default.
• W2149771890 countsByYear W21497718902019 @default.
• W2149771890 countsByYear W21497718902020 @default.
• W2149771890 countsByYear W21497718902021 @default.
• W2149771890 countsByYear W21497718902022 @default.
• W2149771890 countsByYear W21497718902023 @default.
• W2149771890 crossrefType "journal-article" @default.
• W2149771890 hasAuthorship W2149771890A5014640874 @default.
• W2149771890 hasAuthorship W2149771890A5018711955 @default.
• W2149771890 hasAuthorship W2149771890A5033935778 @default.
• W2149771890 hasAuthorship W2149771890A5033999259 @default.
• W2149771890 hasAuthorship W2149771890A5036532882 @default.
• W2149771890 hasAuthorship W2149771890A5041469238 @default.
• W2149771890 hasAuthorship W2149771890A5043893807 @default.
• W2149771890 hasAuthorship W2149771890A5046222147 @default.
• W2149771890 hasAuthorship W2149771890A5050929435 @default.
• W2149771890 hasAuthorship W2149771890A5065548109 @default.
• W2149771890 hasAuthorship W2149771890A5074542184 @default.
• W2149771890 hasAuthorship W2149771890A5078383767 @default.
• W2149771890 hasAuthorship W2149771890A5080736266 @default.
• W2149771890 hasBestOaLocation W21497718901 @default.
• W2149771890 hasConcept C121608353 @default.
• W2149771890 hasConcept C126322002 @default.
• W2149771890 hasConcept C164705383 @default.
• W2149771890 hasConcept C2776694085 @default.
• W2149771890 hasConcept C2778198053 @default.
• W2149771890 hasConcept C2778233292 @default.
• W2149771890 hasConcept C2779804826 @default.
• W2149771890 hasConcept C2780074459 @default.
• W2149771890 hasConcept C2780456651 @default.
• W2149771890 hasConcept C500558357 @default.
• W2149771890 hasConcept C71924100 @default.
• W2149771890 hasConcept C90924648 @default.
• W2149771890 hasConceptScore W2149771890C121608353 @default.
• W2149771890 hasConceptScore W2149771890C126322002 @default.
• W2149771890 hasConceptScore W2149771890C164705383 @default.
• W2149771890 hasConceptScore W2149771890C2776694085 @default.
• W2149771890 hasConceptScore W2149771890C2778198053 @default.
• W2149771890 hasConceptScore W2149771890C2778233292 @default.
• W2149771890 hasConceptScore W2149771890C2779804826 @default.
• W2149771890 hasConceptScore W2149771890C2780074459 @default.
• W2149771890 hasConceptScore W2149771890C2780456651 @default.
• W2149771890 hasConceptScore W2149771890C500558357 @default.
• W2149771890 hasConceptScore W2149771890C71924100 @default.
• W2149771890 hasConceptScore W2149771890C90924648 @default.
• W2149771890 hasIssue "7" @default.
• W2149771890 hasLocation W21497718901 @default.
• W2149771890 hasLocation W21497718902 @default.
• W2149771890 hasOpenAccess W2149771890 @default.
• W2149771890 hasPrimaryLocation W21497718901 @default.
• W2149771890 hasRelatedWork W1864361583 @default.

• next